Quantum-Si Inc
Quantum-Si Inc (QSI) filed an SEC Form 8-K — Regulation FD Disclosure. 1 ProteusTM The Future of Single-molecule Protein Sequencing World HUPO 2026 Exhibit 99.1 2 Disclaimer and Other Information Forward-looking Statements This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States
Quantum-Si (QSI) reported interim data comparing its Proteus platform with Platinum Pro, showing significant performance improvements in sequencing metrics. Proteus outperformed Platinum Pro in scale, accuracy, and protein identification. The data was presented at the 2026 World HUPO Congress. Quantum-Si expects further improvements before Proteus' launch in Q2 2027.
Quantum-Si (NASDAQ:QSI) reported Q2 2026 revenue of $344,000, down from $591,000 a year earlier, and a Q2 net loss of $23.5 million. The company said Proteus launch timing is revised to early 2027, with initial detection of 19 or 20 amino acids. It expects about $12 million annual operating-expense savings and full-year 2026 revenue near $1 million.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning QSI (Quantum-Si Inc). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent QSI coverage spans earnings, technology and corporate actions.
In the last 30 days, QSI insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($39K). The most active reporter was Keyes Jeffry R., Chief Financial Officer, with 2 filings.
The filing provides no new financial numbers, only risk disclosures and product development plans, likely keeping the stock neutral to slightly negative as uncertainties are highlighted.
Positive technical advantage may boost investor sentiment, but product is still in development.
The call updates Proteus execution timeline and expected amino-acid detection range, alongside cash runway and cost-savings timing.
The print is a modest positive versus consensus, but the article flags that near-term follow-through depends on management commentary and updated estimate revisions.
Earnings confirm continued losses and low revenue scale, likely keeping valuation and financing risk in focus.
AlphAI scores every news story that mentions QSI with an AI model for sentiment and relevance, and aggregates insider trades from Quantum-Si Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Quantum-Si Inc (QSI) filed an SEC Form 8-K — Regulation FD Disclosure. 1 ProteusTM The Future of Single-molecule Protein Sequencing World HUPO 2026 Exhibit 99.1 2 Disclaimer and Other Information Forward-looking Statements This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States
1 min readQuantum-Si (QSI) reported interim data comparing its Proteus platform with Platinum Pro, showing significant performance improvements in sequencing metrics. Proteus outperformed Platinum Pro in scale, accuracy, and protein identification. The data was presented at the 2026 World HUPO Congress. Quantum-Si expects further improvements before Proteus' launch in Q2 2027.
2 min readQuantum-Si (NASDAQ:QSI) reported Q2 2026 revenue of $344,000, down from $591,000 a year earlier, and a Q2 net loss of $23.5 million. The company said Proteus launch timing is revised to early 2027, with initial detection of 19 or 20 amino acids. It expects about $12 million annual operating-expense savings and full-year 2026 revenue near $1 million.
6 min readQuantum-Si Incorporated (QSI) reported Q2 adjusted EPS loss of $0.11, better than the Zacks Consensus loss of $0.13. Revenue was $0.34 million, up 4.24% versus the estimate, down from $0.59 million a year earlier. The article cites a Zacks Rank #3 (Hold) and notes upcoming consensus for the next quarter EPS of -$0.13 on $0.27 million revenue.
6 min readQuantum-Si Inc. (QSI) reported Q2 2026 revenue of $344,000, above an analyst estimate of $305,020. Diluted EPS was -$0.11, slightly better than expected. The company posted gross profit of $172,000 and an operating loss of $25.6 million, with net loss of $23.5 million. Cash was $23.7 million. Shares fell 1.19% after the release.
4 min readQuantum-Si (Nasdaq: QSI) reported Q2 2026 revenue of $344k during the Platinum-to-Proteus transition, down from $591k a year earlier. It updated the Proteus launch to Q2 2027, cut about 20% of staff, and expects annualized operating expense savings of about $12m. Cash runway extends to Q4 2028; cash and investments were $169.9m at June 30, 2026.
4 min readQuantum-Si Inc (QSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quantum-Si Reports Second Quarter 2026 Financial Results and Provides Proteus™ Development Update Company updates anticipated commercial launch of Proteus to Q2 2027, cost-reduction actions expected to extend cash runway into Q4 2028 and highlights estimated new mark
6 min readQuantum-Si Inc. (QSI) faces a second Nasdaq delisting risk after its Class A shares closed below $1 for 30 straight business days, according to a July 24 SEC filing. Shares traded around 78 cents, down about 29% YTD. Nasdaq gives until Jan. 19, 2027 to regain compliance. Q1 revenue was $258,000 and net loss $21.7 million.
5 min readQuantum-Si Inc (QSI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex101sdleaseagreement.htm EX-10.1 ex101sdleaseagreement EXHIBIT 10.1 LEASE Between STERLING CITY SCIENCE SOUTH DEVELOPMENT, LLC, a Delaware limited liability company as Landlord and QUANTUM-SI INCORPORATED, a Delaware corporation as Tenant For certain premises at 9955 P
4 min readQuantum-Si Inc.'s CFO, Jeffry R. Keyes, was granted 780,847 stock options with an exercise price of $0.976 per share, expiring in 2036, and 652,803 restricted stock units (RSUs). These awards are compensation grants, not open-market transactions, and are subject to multi-year vesting schedules contingent on his continued employment. Following these grants, Keyes directly holds 1,816,000 shares of Class A common stock.
2 min read
